에모뎁시드 및 프라지콴텔

국소용 항기생충제 (선충구제제; 조충구제제)

**에모뎁시드/프라지콴텔**(일반적인 상품명: 프로펜더®)은 주로 고양이용으로 승인된 광범위 국소 도포용 항기생충 복합제입니다. * **에모뎁시드**는 새로운 시클로옥타뎁시펩티드 계열로 선충류(회충 및 구충)에 대해 탁월한 효능을 제공합니다. * **프라지콴텔**은 잘 알려진 이소퀴놀린-피라진 유도체로 조충류(촌충)에 매우 효과적입니다. **임상 요점:** * 국소 도포 제형은 알약을 먹이기 어려운 고양이 환자에게 큰 장점을 제공하며, 반려동물과 보호자 모두의 스트레스를 최소화합니다. * 고양이용으로 승인되었으나, 경구 투여가 어려운 파충류 등 특수동물 임상에서 허가 외(off-label)로 사용되기도 합니다. * 피부를 통해 전신으로 흡수되므로, 위장관 부작용을 방지하고 정확한 용량이 투여되도록 동물이 도포 부위를 핥지 못하게 하는 것이 매우 중요합니다.

작용 기전: The combination utilizes two distinct mechanisms to eradicate parasites: * **Emodepside (Nematocide):** Binds pre-synaptically at the neuromuscular junction to a **latrophilin-like receptor** → increases intracellular calcium and diacylglycerol → triggers fusion of vesicles containing inhibitory neuropeptides → releases **PF1- and/or PF2-like receptors** into the synaptic cleft → stimulates postsynaptic receptors. This cascade results in the profound inhibition of pharyngeal pumping and locomotion, leading to **flaccid paralysis and death** of the nematode. * **Praziquantel (Cestocide):** Interacts with phospholipids in the parasite's integument → causes rapid intracellular ion fluxes (sodium, potassium, and **calcium**) → induces severe, irreversible tetanic contraction of the worm's musculature. At higher concentrations, it causes irreversible focal vacuolization and subsequent disintegration of the cestodal integument, making the parasite susceptible to the host's immune system.

동물 종별 용량

Cats

Treatment and control of hookworm, roundworm, and tapeworm infections · Minimum dose is 3 mg/kg emodepside & 12 mg/kg praziquantel applied to the skin on the back of the neck as a single topical dose. If re-infection occurs, the product can be re-applied after 30 days. · topical · once · Single dose · A second treatment should not be necessary unless re-infection occurs.

Reptiles

Parasitic infections (off-label) · 4 drops/100 g body weight · topical · once · Single dose · Aquatic species must be kept in a dry place for 48 hours after treatment. Caution is advised until further studies verify safety and efficacy, particularly in sick animals.

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

topical

금기

Cats less than 8 weeks of age
Cats weighing less than 1 kg (2.2 lb)

이상반응

Application site reactions (alopecia, dermatitis, pyoderma, edema, erythema, pruritus)
Salivation/hypersalivation (especially if licked)
Lethargy
Vomiting
Diarrhea
Agitation or nervousness
Tremors or twitching
Ataxia
Eye or respiratory irritation
Rare post-approval reports: facial swelling, rear leg paralysis, seizures, hyperesthesia, morphea-like (scleroderma) lesion

약물 상호작용

P-glycoprotein inhibitors/substrates (e.g., ivermectin, erythromycin, prednisolone, cyclosporine) · Emodepside is a P-glycoprotein substrate; concurrent use may cause pharmacokinetic interactions and potentially increase toxicity or alter efficacy.

모니터링

Clinical efficacy (resolution of clinical signs, negative fecal flotation/sedimentation)

과용량

Both drugs generally have a wide margin of safety. * **Topical Overdose:** In 8-week-old kittens treated topically at 5X the recommended dose, transient salivation and/or tremors were observed but were self-limiting. In 7- to 8-month-old cats treated at 10X the dose, transient salivation, tremor, and lethargy occurred. * **Oral Exposure:** Accidental oral ingestion (e.g., licking the application site) can cause salivation, vomiting, anorexia, tremors, abnormal respirations, and ataxia. These signs typically resolve without specific treatment. * **Praziquantel Toxicity:** Parenteral doses of 50-100 mg/kg in cats caused transient ataxia and depression; injected doses of 200 mg/kg were lethal.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.